A research team maps the key tasks that define modern enzyme engineering—function annotation, structure modeling, and property prediction—and explain how AI methods now accelerate each step, from ...

A research team has delivered an overview of how computational tools are reshaping the design of nonnatural metabolic pathways—engineered biochemical routes that do not exist in nature but enable ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Organs often have fluid-filled spaces called lumens, which are crucial for organ function and serve as transport and delivery ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

Dec 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, its once-weekly ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...